IL-23 Inhibitors
Source
- Human
Mechanism of Action
- Monoclonal IgG1 Lambda binds P19 of IL23
Pregnancy Category
- No Known Data
Dose
- Subcutaneous
- 100 mg at weeks 0 and 4 then every 8 weeks
Indications
- FDA Dermatology: Psoriasis and Psoriatic arthritis
- Off label: Hidradenitis suppurativa
Contraindications
- Hypersensitivity reaction
- Infection
- Live vaccines
- Malignancy
Side effects
- Injection site reaction
- URTI
- Headache
- Arthralgia
Notes
- PASI75 in 80-90%
Source
- Humanized
Mechanism of Action
- Monoclonal IgG1 Kappa binds P19 of IL23
Pregnancy Category
- No known data
Dose
- Subcutaneous
- 150 mg at weeks 0 and 4 then every 12 weeks
Indications
- FDA approved for Psoriasis
Contraindications
- Hypersensitivity reaction
- Infection
- Live vaccines
- Malignancy
Side effects
- Injection site reaction
- URTI
- Headache
- Arthralgia
Notes
- 82% PASI90
Source
- Humanized
Mechanism of Action
- Monoclonal IgG1 Kappa Binds P19 of IL23
Pregnancy Category
- No Known Data
Dose
- Subcutaneous
- 100 mg at weeks 0 and 4 then every 12 weeks
Indications
- FDA approved for Psoriasis
Contraindications
- Hypersensitivity reaction
- Infection
- Live vaccines
- Malignancy
Side effects
- Injection site reaction
- URTI
- Headache
- Arthralgia
Notes
- 78% PASI75
Source
- Humanized
Mechanism of Action
- Monoclonal antibody against IL23
Pregnancy Category
- No known data
Dose
- IV
Indications
- Phase II trial
Contraindications
- No known data